Calcium and Vitamin D Flashcards
1
Q
Calcium Homeostasis
A
- Goal is to have constant level of ionized calcium is extracellular fluid while still providing enough calcium to cells, bones, and for renal excretion.
- Hormones involved in calcium homeostasus are able to act on the gut, bone, and renal tubules.
- PTH and 1,25(OH)2D
2
Q
Secretion of PTH
A
- Secreted by parathryoid glands
- PTH is under tight control of serum calcium. In order to release PTH, parathyroid cells use calcium sensing receptors (CaSR) to determine Ca2+ levels in the body. In parathryoid glands activation of CaSR leads to inhibition of PTH secretion.
3
Q
Biological Effects of PTH
A
- Regulates serum ionized calcium levels by working on 3 main targets.
- Bone - increase bone reabsorption to release calcium (also results in release on phosphate. It is important that phosphate secretion increases at kindey, because phosphate can also stimulate PTH via increase RANKL and decreased OPG secretion by osteoblasts.
- Intestinal muscosa - indirect. Results from increase production of active vitamin D metabolite
- Kidney - direct effect on tubular reabosorption of calcium, phosphate, and bicarbonate. See increase in calcium reabsorption and decrease in phosphate reabsorption.
4
Q
Calcitonin
A
- Main function is to inhibit osteoclast mediated bone resorption. Also inhibits calcium uptake/reabsorption in the kidneys and intestine.
- Secreted by parafollicular C cells of the thyroid - use CaSR to sense changes in calcium levels in the body (release in response to increasing calcium).
- Calcitonin does not likely play an essential role in homeostasis.
5
Q
Function of Vitamin D
A
- To be biologically active, vitamin D must be metabolized further. The live is the main organ capable of metabolizing vitamin D to 25(OH)D. The kidney then converts it to 1,25(OH)2D
- Vitamin D functions in the regulation of calcium and phosphate homeostasis in conjuction with PTH.
- Intestines - regulates calcium transport through intestinal epithelium (increase Ca2+ and phosphate absorption).
- Bone - Stimuates osteoblasts to secrete RANKL, thereby activating osteoclasts to resorb bone to raise serum calcium levels.
- Kidney - Plays role in stimulating calcium and phosphate reabsorption.
6
Q
Function of Bone
A
- Provides rigit support to extremities and body cavities containing vital organs
- Locomotion - provides levers and sites of attachment for muscles
- Provide large reservoir of ions critical for life
- House hematopoietic elements
7
Q
- RANKL
- OPG
A
- RANKL - Expressed on osteoblasts. Binding of RANKL to RANK stimualtes osteoclasts formation, differentiation, and activation
- OPG - Release by osteoblasts. Inhibits RANK by binding RANKL, thereby preventing its interaction with RANK.
8
Q
Osteoporosis
Primary and Secondary
A
- Condition of low bone mass and microarchitectural disruption that results in fractures with minimal trauma.
- Primary osteoporsis - reduced bone mass and fractures in postmenopausal women or in older men and women due to age-related factors.
- A bone loss resulting from specific clinical disorders. EX. thryrotoxicosis or hyperadenocorticism.
9
Q
Fragility-related fractures
A
- Due to trauma equal to or less than a fall from standing position.
- Common sites - vertebral bodies, distal forearm, and proximal femur
- Vertebral compressur factures are the most common.
10
Q
Risk Factors for Osteoporosis
A
- Hereditary factors resulting in low peak bone mass
- Circulating gonadal steriods - estrogen acts on multiple cells via estrogen receptors. Thus, decreased estrogen increases bone resorption caused by increased osteoclast. Bone cells dont have receptors for testosterone, but it has an affect indirectly through local aromatization to estrogen.
- Physical activity - activity impses strain on skeletal system, resulting in microtrauma and appropriate bone remodelling and strengthening.
- Nutrient intake - insufficient calcium intake, vitamin D, deficiency (leads to secondary hyerparthryodisims and accerlated bone loss).
- Smoking - have direct toxic effects on osteoblasts; alters estrogen metabolism leadig to ealier menopause.
- Certain illness are associated with osteoporosis
- GI diseases that result in impaired absorption of bone minerals and vitamin D (i.e., celiacs and crohns)
- Hypogondal states
- Endocrine disorders - cushings, hyperparathryoidism
- Certain medications are associated with osteoporosis
- Glucocoticoids
- Aromatase inhibitors
- Thyroid hormones
11
Q
Bone loss and estrogen deficiency
A
- Estrogen is important for bone mass, and low levels are associated with bone loss with estrogen deficiency OPG secretion is low. This allows strong response of osteoclast precursors with RANKL and increases bone resorption. Furthermore, increased bone resorption will result in incease extracellular calcium -> decreased PTH -> increase calciuria, decreased renal production of 1,25(OH)2D and decrease intestinal calcium.
- Thus, you see a net loss of calcium
12
Q
Bone loss and age
A
- Deficits in renal and intestinal function impact body calcium levels. With advancing age we see:
- Decreased efficiency in vitamin D production by the skin
- Decreased ability of the kidney to convert vitamin D to active form
- Intestinal absorption of calcium becomes less efficient
- Hypersecretion of PTH resulting in increase bone remodelling and accelerated bone loss.
13
Q
Diagnosis of Osteoporosis
A
- Patient sustained fragility fracture
- Bone densitometry - all women >65, all men >70, and men and women with increase risk factors for fractures should be screened with bone densitometry to osteoporosis.
- BMD more than 2.5SD below the age-matched normal reference population indicate osteoporosis. Values between -1.0 and -2.5SD are categorized as low bone density.
14
Q
Treatment of osteoporosis
A
- Medications are used to treat or prevent act either by decreasing rate of bone resorption or by increasing bone formation.
- Antiresorptive agents:
- Calcium
- Vitamin D and calcitriol
- Estrogen
- Selective estrogen receptor modulators
- Calcitonin
- Bisphosphonates
- RANKL inhibition
- Bone-forming agents:
- Fluoride
- Androgens
- Parathyroid hormone
- Strontium ranelate
15
Q
Antiresporitve agents osteoporosis
A
- Calcium supplementation of 1000-2000mg/day in doses of ≤ 600mg to maximize absorption is recommended.
- Vitamin D and Calcitriol - Vitamin D supplementation in individuals with marginal or deficiency vitamin D status improves intestinal calcium absorption, suppresses PTH and bone remodeling, increases bone mass, and reduced fracture risk. Used of vitamin D metabolties, such as calcitriol, may increase ability to interact with parathyroid cells and suppress PTH secretion directly.
- Estrogen - Increases BMD, however, protective effects dissipates within a few years of cessation. With balance with increase risk of breast cancer, CVD, and VTE (not considered as a first line therapy because of risks).
-
Oral bisphosphonates - first -line therapy. Binds avidly to hydroxyapatite crystals, particulary at sites of active remodeling. They interfere with protein prenylation in osteoclast, impairing osteoclast bone resorption and enhancing osteoclast apoptosis. Reduce vertebral fracture by 50-60% and also reduce risk of non-vertebral fractures.
- Contraindications - patients with esophageal disorders, patients who are unable to follow dosing requirements (stay upright for 30-60mins), patients with eGFR<30
-
RANKL inhibition - inhibits osteoclast formation, decreases bone resorption, increases BMD, and reduced risk of fracture. Binds to RANKL to block the binding of RANKL to RANK reducing the function and survival of osteoclasts which results in decrease bone resorption and increase bone density. Not considered an initial therapy, can be used in those where oral bisphosphonates are contraindicated.
*